Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients

• Authors: Markus Cornberg, Hannover Medical School Hannover; Christiane S Eberhardt, Emory University
• Journal Title: JOURNAL OF HEPATOLOGY
• Volume: Volume 75, Number 2
• Publisher: Elsevier | 2021-08-01, Pages 265-266
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1016/j.jhep.2021.05.007
• Subjects: Health Sciences, Obstetrics and Gynecology
• Keywords: Cirrhosis; liver transplantation; vaccine; COVID-19; SARS-CoV-2

Abstract

Immunocompromised patients and those with cancer were excluded from the phase III trials of current COVID-19 vaccines and limited data are available on patients with chronic liver disease (CLD). This led the European Association for the Study of the Liver (EASL) to publish a position paper guiding COVID-19 vaccination in patients with CLD, hepatobiliary cancer, and liver transplant recipients (LTRs).1 In this issue, Wang et al. 2 and Rabinowich et al. 3 report initial data on COVID-19 vaccination in patients with non-alcoholic fatty liver disease (NAFLD) and in LTRs, respectively.